Literature DB >> 11802752

Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species.

Sara E Cosgrove1, Keith S Kaye, George M Eliopoulous, Yehuda Carmeli.   

Abstract

BACKGROUND: This study evaluated the clinical and economic impact of the emergence of third-generation cephalosporin-resistant Enterobacter species.
METHODS: Mortality, length of hospitalization, and hospital charges were examined in a cohort that was selected from a group of 477 patients with initial cultures that yielded a third-generation cephalosporin-susceptible Enterobacter species. Case patients (n = 46) had subsequent cultures yielding a third-generation cephalosporin-resistant Enterobacter species. Control patients (n = 113) who did not develop resistance were matched to cases on site of Enterobacter infection and length of hospitalization prior to isolation of the initial susceptible organism. Multivariable analyses were used to adjust for confounding.
RESULTS: Twenty-six percent of cases died vs 13% of controls (P =.06). The median total hospital stay for cases was 29.5 days (interquartile range [IQR], 20-60) and 19 days for controls (IQR, 13-27; P<.001). The median hospital charge for cases was $79 323 (IQR, $34 546-$161 384) and for controls was $40 406 (IQR, $18 470-$79 005; P<.001). After adjusting for comorbidities, severity of illness, intensive care unit admission, surgery, transfer from another hospital, sex, and age, emergence of resistance was associated with increased mortality (relative risk, 5.02; P =.01), hospital stay (1.5-fold, P<.001), and hospital charges (1.5-fold, P<.001). Emergence of resistance had a median attributable hospital stay of 9 days and an average attributable hospital charge of $29 379.
CONCLUSIONS: Emergence of antibiotic resistance in Enterobacter species results in increased mortality, hospital stay, and hospital charges. Minimizing resistance in Enterobacter species should be a priority.

Entities:  

Mesh:

Year:  2002        PMID: 11802752     DOI: 10.1001/archinte.162.2.185

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  57 in total

1.  Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel.

Authors:  Jacob Schlesinger; Shiri Navon-Venezia; Inna Chmelnitsky; Orly Hammer-Münz; Azita Leavitt; Howard S Gold; Mitchell J Schwaber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Effect of antibiotic heterogeneity on the development of infections with antibiotic-resistant gram-negative organisms in a non-intensive care unit surgical ward.

Authors:  Yoshio Takesue; Hiroki Ohge; Mitsuru Sakashita; Takeshi Sudo; Yoshiaki Murakami; Kenichiro Uemura; Taijiro Sueda
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

3.  Patterns of antimicrobial use among nursing home residents with advanced dementia.

Authors:  Erika D'Agata; Susan L Mitchell
Journal:  Arch Intern Med       Date:  2008-02-25

4.  Influence of provider and urgent care density across different socioeconomic strata on outpatient antibiotic prescribing in the USA.

Authors:  Eili Y Klein; Michael Makowsky; Megan Orlando; Erez Hatna; Nikolay P Braykov; Ramanan Laxminarayan
Journal:  J Antimicrob Chemother       Date:  2015-01-20       Impact factor: 5.790

5.  Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.

Authors:  M J Dinubile; I Friedland; C Y Chan; M R Motyl; H Giezek; M Shivaprakash; R A Weinstein; J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-07       Impact factor: 3.267

6.  Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.

Authors:  Mark J DiNubile; Joseph W Chow; Vilas Satishchandran; Adam Polis; Mary R Motyl; Murray A Abramson; Hedy Teppler
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections.

Authors:  Bingyun Li; Thomas J Webster
Journal:  J Orthop Res       Date:  2017-08-11       Impact factor: 3.494

8.  Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.

Authors:  Lorna E T Stearne; Doret van Boxtel; Nicole Lemmens; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Mutants resistant to LpxC inhibitors by rebalancing cellular homeostasis.

Authors:  Daina Zeng; Jinshi Zhao; Hak Suk Chung; Ziqiang Guan; Christian R H Raetz; Pei Zhou
Journal:  J Biol Chem       Date:  2013-01-11       Impact factor: 5.157

10.  Adherence to Hospital Antibiotic Policy for Treatment of Escherichia coli ESBL in Urine.

Authors:  R Someshwaran; K Gnana Prakash; Shreeram A Deshpande; Anbu N Aravazhi
Journal:  J Clin Diagn Res       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.